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ABSTRACT
The purpose of writing this review on gastroretentive drug delivery systems (GRDDS) was to compile the recent literature with a special focus on 
various gastroretentive approaches that have recently become leading methodologies in the field of site-specific orally administered controlled release 
drug delivery. One of the complex processes in the human body is gastric emptying, as it is highly variable, which makes the in vivo performance of the 
drug delivery systems uncertain. GRDDS has gained immense popularity in the field of oral drug delivery recently. It is a widely employed approach to 
retain the dosage form in the stomach for an extended period of time and release the drug slowly that can address many challenges associated with 
the conventional oral delivery system. Conventional drug delivery systems may not overcome the issues imposed by the gastrointestinal tract (GIT) 
such as incomplete release of drugs, decrease in dose effectiveness, and frequent dose requirement. To overcome this variability, a controlled drug 
delivery system with a prolonged gastric residence time of >12 h in the stomach can be of great practical importance for drugs with an absorption 
window in the upper small intestine. GRDFs enable prolonged and continuous release of the drug to the upper part of the GIT and thus significantly 
extend the duration of drug release and improve the bioavailability of drugs that have a narrow therapeutic window; by this way, they prolong dosing 
interval and increase compliance.
Keywords: Gastroretentive, Floating microsphere, Gastric residence time, Therapeutic window.
INTRODUCTION
Gastroretentive drug delivery system (GRRDS)
Oral controlled-release (CR) dosage forms (DFs) were developed over 
the past three decades due to their therapeutic benefits, for example, 
ease of administration, patient compliance, and malleability to the 
formulation.
However, this is due to several physiological difficulties such as the 
inability to bring under control and detect controlled drug delivery 
systems within the preferred region of the gastrointestinal tract (GIT) 
due to variable gastric emptying and motility Fig. 1.
Besides, relatively brief gastric emptying time (GET) in humans that 
typically averages 2–3 h through the main absorption zone, that is, the 
stomach and the upper part of the intestine, in releasing incomplete 
medication from the drug delivery system can release efficacy of the 
administered dose [1].
For more than half a century, pharmaceutical scientists have focused 
on the development of ideas to increase the gastric residence time of 
DFs [2]. The prolonged residence of DFs in the stomach, known as gastric 
retention, has various therapeutic and biopharmaceutical properties. 
Improvement of local activity in the stomach, increased concentrations 
in the stomach, increased patient compliance due to dose reduction 
or improved bioavailability of some drugs with windows in the upper 
GIT [3].
The DFs that can be maintained in the stomach are called 
gastrointestinal drug delivery systems (GRDDS). Controlled delivery 
of drugs can improve the absorption window as shown in Fig. 2. 
Prolonged gastric retention improves bioavailability, reduces residual 
waste, and increases the solubility of drugs soluble in the high pH 
environment of the GIT. This includes applications for local delivery of 
the stomach and small intestine [4].
ANATOMY OF THE GIT
The GIT can be divided into three main areas:
1. Stomach
2. Small intestine – duodenum, jejunum, and ileum
3. Large intestine.
The GIT is a continuous muscular tube, which extends from the mouth 
to the anus, which serves to take nutrients and eliminate waste by such 
physiological processes as secretion, motility, digestion, absorption, and 
excretion. The stomach is a J-shaped enlargement of the gut GIT that 
can be divided into four anatomic regions: The cardia, fundus, body, and 
antrum. The main function of the stomach is to store and mix food with 
gastric secretions before emptying its load (chime) through the pyloric 
sphincter and into the small intestine at a controlled rate suitable for 
digestion and absorption. When empty, the stomach has a volume of 
about 50 ml, [5] it can grow up to 1 L when full. The walls of the GIT, 
from the stomach to large intestine, have the same basic arrangement 
of tissues, different layers, from outside to inside, including the serosa, 
longitudinal muscle, endocrine planetary, circular muscle, submucosa, 
muscular mucosa, lamina propria, and contains epithelium [6].
In addition to longitudinal and circular muscle, the stomach has a third 
muscle layer known as the “oblique muscle layer,” which is located in 
the proximal stomach, branching above the fundus and upper regions of 
the gastric body. The different smooth muscle layers are responsible for 
performing the cruise functions of the gastric emptying and intestinal 
transit, that is, GIT.
MUCUS: STRUCTURE, FUNCTION, AND COMPOSITION
Mucus is a complex viscous adjacent secretion synthesized by specialized 
goblet cells. These goblet cells are glandular columnar epithelium cells 
and line all organs, exposure to the external environment [7]. Mucus is 
a complex viscous adjacent secretion synthesized by specialized goblet 
cells. These goblet cells are glandular columnar epithelium cells and line 
© 2021 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons.org/
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all organs, exposure to the external environment. Mucus is found to carry 
out many functions within these locations, for instance, lubrication for the 
passage of objects, maintenance of a hydrated epithelium layer, a barrier 
function concerning pathogens and toxins, and as a gel layer allowing for 
the exchange of gases and nutrients from the underlying epithelium [8].
Mucus is composed mainly of water (>95%) and mucin, which is 
composed of an exceptionally high molecular weight (2–14 × 106 g/
mol) of glycoprotein. Also found within this “viscoelastic soup” are 
proteins, lipids, and mucopolysaccharides, which are found in smaller 
proportions (<1%). Mucin glycoproteins form a highly entangled 
network of macromolecules that bind to each other via non-covalent 
bonds. Such a molecular association is central to the structure of mucus 
and is responsible for its rheological properties. Besides, the mucosa is 
treated as ionic polyelectrolyte in the reduction of pendant sialic acid 
(pKa = 2.6) and sulfate groups located on glycoprotein molecules [9].
Other non-mucin components of mucus include secretory IgA, lysozyme, 
lactoferrin, lipids, polysaccharides, and various other ionic species. 
Some of these non-mucin components are believed to be responsible 
for the bacteriostatic mucus [10]
POTENTIAL DRUG CANDIDATES FOR GRDDS
•	 A small window in the GI tract, for example, riboflavin and levodopa
•	 It is primarily absorbed from the stomach and upper part of GIT, for 
example, calcium supplements, chlordiazepoxide, and cinnarizine
•	 Drugs that act locally in the stomach, such as antacids and misoprostol
•	 Drugs that degrade in the colon, such as ranitidine HCl and 
metronidazole
•	 Drugs that disturb common colonic bacteria, for example, amoxicillin 
trihydrate
•	 Low-density form of the DF that causes buoyancy in gastric fluid
•	 High-density DF that remains intact in the bottom of the stomach
•	 Bioadhesion to abdominal mucosa
•	 Slow motility of the GIT by concomitant administration of drugs or 
excipients
•	 Inflammation or spread of a larger size that limits DF emptying 
through the pyloric sphincter [11].
BASIC GIT PHYSIOLOGY
Anatomically, the stomach is divided into three areas: fundus, body, and 
antrum (pylorus). The fundus and the proximal part of the body act as a 
reservoir of non-digestible substances, while the antrum is the main site 
for a combination of movements and acts as a pump for gastric emptying 
through the moving process. Gastric emptying occurs in fasting and feeding 
states. However, the dynamics of the two states are different. During a 
state of fasting, cycling through the stomach and intestines, a series of 
electrical events occur every 2–3 h. This is called the Inter-Digestive Milo 
Electric Cycle or Migrating Milo Electric Cycle (MMC), which is divided into 
the following four steps described by Wilson and Washington (1989).
1. Phase I (basal stage) lasts 40–60 min with rare contractions
2. Phase II (pre-burst phase) often lasts 40–60 min with action 
potentials and contractions. As the phase increases, the intensity 
and frequency and frequency gradually increase
3. Phase III (burst phase) lasts 4–6 min. It involves short-term severe 
and frequent contractions. This wave touches everything from the 
stomach to the small intestine. This is also known as the housekeeper 
wave
4. Phase IV lasts from zero to five minutes and takes place between two 
cycles of Phase III and I, respectively Fig. 3 [13].
After a mixed meal, the method of contractions varies from fasting to 
feeding. This is also known as the digestive movement pattern and has 
frequent contractions such as the second stage of the fasting phase. As 
a result of these contractions, the size of the food particle is reduced 
(<1 mm), leading to pylorus in suspension form. In a fed state, MMC 
initiation is delayed, which reduces the gastric emptying rate. Scientific 
studies determining gastric emptying rates have shown that orally-
CR DFs are two problems, namely low GET and unexpected gastric 
emptying rate [14,15].
Fig. 3: Motility patterns of the gastrointestinal tract in the fasted 
state
Fig. 1: Diagram of the human stomach
Fig. 2: Drug absorption from (a) conventional dosage forms and 
(b) gastroretentive drug delivery system [12]
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APPROACHES TO GASTRIC RETENTION
Many methods have been used to increase the gastric retention time 
(GRT) of the DF in the stomach by applying a variety of concepts. These 
include in Fig. 4.
FLOATING SYSTEMS
Floating systems are low-concentration systems that are buoyant 
enough for the stomach to flow above the gastric contents. When the 
system flows above the gastric contents, the rate is slowly released at 
the desired rate, thereby increasing gastroretention time and reducing 
fluctuations in plasma drug concentrations [16,17].
BIO/MUCOADHESIVE SYSTEMS
The bio/mucoadhesive system (Fig. 5) works as a means of increasing 
the gastric residence time of the drug delivery system in the stomach by 
binding to the gastric epithelial cell surface or with mucins. The binding 




•	 Receptor-mediated synthesis [16].
SWELLING AND EXPANDING SYSTEMS
These are DFs that prevent the outflow of pylorus after swallowing. As a 
result, the DF lasts longer in the stomach. These systems can be named 
“plug type systems” because they show a tendency to penetrate the 
pyloric sphincter Fig. 6 [18].
HIGH-DENSITY SYSTEMS
These systems Fig. 7, with a density of about 3 g/cm3, persist in 
the abdominal cavities and can prevent its gradual contraction. A 
density of 2.6–2.8 g/cm3 serves as a threshold value after which 
such systems can be maintained in the lower abdomen. High-density 
aggregates include coated pellets. The coating is made of heavy inert 
substances such as barium sulfate, zinc oxide, titanium dioxide, and 
iron powder [19].
INCORPORATION OF PASSAGE DELAYING FOOD AGENTS
Edible excipients such as fatty acids, for example, the salts of myristic 
acid, alter and modify the outline of the stomach in a tight state, thus 
reducing the rate of gastric emptying and prolonging the release. The 
delay in gastric emptying after the fatty diet is primarily a chain length 
of saturated fatty acids of C10-C14.
ION EXCHANGE RESINS
Ion exchange resins are loaded with bicarbonate and bind to a negatively 
charged drug residue. The resulting beads are then encapsulated into 
a semi-permeable membrane to overcome the rapid loss of carbon 
dioxide. When it reaches the acidic environment of the stomach, there 
are ions exchange of chlorides and bicarbonates occour. As a result of 
this reaction, carbon dioxide is released into the membrane, producing 
a temporary layer of resin beads, which, unlike the unbleached beads, 
causes the beads to rise above the gastric contents.
OSMOTIC REGULATED SYSTEMS
It is equipped with an osmotic pressure controlled drug delivery device 
inflatable floating support in a biodegradable capsule. The capsule in 
the stomach quickly disintegrates, leaving the intragastric osmotically 
controlled drug delivery device. The inflatable support inside forms a 
malfunctioning hollow polymer bag containing a liquid that gasifies 
to inflame the bag at body temperature. The osmotic controlled 
drug delivery device has two components – the drug store and the 
osmotically active compartment [16].
FLOATING DRUG DELIVERY SYSTEMS
Floating drug delivery systems or hydrodynamic balance systems have 
a lower density than abdominal fluid and stay in the stomach for longer 
without affecting the rate of miscarriage Fig. 4. The drug is slowly released 
from the system at the desired rate and the other drug is released into 
the stomach. This results in better control of the duration of stay in the 
stomach and the suitability of plasma drug concentrations [20].
Floating systems are low-level systems that have enough courage 
to float beyond the stomach contents and remain in the stomach for 
longer. When the system floats above the contents of the stomach, 
the drug is released slowly at the desired rate, leading to an increase 
in intestinal storage time and a decrease in changes in plasma drug 
concentrations [21].
MAGNETIC SYSTEM [16,22]
DFs contain a small internal magnet and a magnet is placed in the 
abdomen over the position of the stomach that retains DF in the gastric 
region.
Disadvantage
•	 The external magnet needs to be positioned with a degree of precision
•	 Patient non-compliance
•	 Not widely used.




Asian J Pharm Clin Res, Vol 14, Issue 1, 2021, 13-26
 Krishna et al.





Volatile liquid containing systems
The GRT of the drug delivery system can be maintained by 
incorporating a fluidized inflatable chamber, namely, ether and 
cyclopentane, which is gasified at body temperature for infection in 
the abdominal chamber. The device may also contain biodegradable 
plugs made of poly (vinyl) alcohol, polyethylene, etc., causing the 
inflatable chamber to slowly melt and fall with gas and collapse after 
a predetermined time to allow spontaneous rejection of the inflatable 
system from the stomach [22].
Gas-generating systems
These buoyant delivery systems use reactions expressed between 
carbonate/bicarbonate salts and citric/tartaric acid to release CO2, 
which is trapped in the gelified hydrochloride layer of the system, thus 
reducing its specific gravity and it floats on the chime [23,24]. These 
incandescent systems contain soluble polymers such as methocel and 
polysaccharides such as chitosan, sodium bicarbonate, citric acid, and 
waste components such as tartaric acid or a liquid-containing chamber 
that is gasified at body temperature. The optimum stoichiometric ratio 
of citric acid and sodium bicarbonate for gas production is reported 
to be 0.76:1. Common approaches to formulate these systems include 
bicarbonate-filled resin structures and coated with ethyl cellulose. The 
coating, which is insoluble but permeable, allows water to penetrate. 
Thus, carbon dioxide is released, allowing the beads to float in the 
stomach. Other approaches and reported materials are a mixture of 
highly soluble hydrocarbons and light mineral oils, a mixture of sodium 
alginate and sodium bicarbonate, multiple-unit floating tablets that 
produce carbon dioxide when sodium bicarbonate, mini capsules 
floating with a core of lactose and polyvinyl pyrrolidone coated with 
hydroxypropyl methylcellulose (HPMC), and floating systems based on 
ion exchange resin technology, etc.
Non-effervescent systems
This mechanism, after swallowing, causes irregular inflammation by 
absorbing gastric fluid, preventing it from exiting the stomach. These 
systems can be referred to as plug type systems because they tend to 
stay close to the pyloric sphincter. One method of manufacturing such 
DFs involves mixing the drug with gel, exposed to gastric fluid after oral 
administration, and maintaining relative integrity of size and less than 
a bulk density in the external gelatinous barrier. The air trapped by the 
inflamed polymer delights these DFs.
Colloidal gel barrier systems
Hydrodynamically balanced system was the first design by Sheth and 
Tossounian in 1975. Such systems consist of hydrochlorides with 
drug-containing gel compositions, which mean that the contents of 
the stomach remain sharp. This system contains high levels of one or 
more gels that form highly soluble cellulose type hydrocarbons, namely, 
HECs, HPMCs, NACMCs, polysaccharides, and polymers form matrices 
such as polycarbophil, polyacrylates, and polystyrene, contained in 
tablets or capsules. When this hydrocarbon system exposed to gastric 
fluid, the  hydrocarbon system hydrates and forms colloidal gel barriers 
around the surface of the gel. The air trapped by the inflated polymer 
has a lower density than unity and limits buoyancy in these DFs [25].
Microporous compartment system
The technique is based on encapsulation of the drug store inside a 
microporous compartment, with an aperture along its top and bottom 
walls. The peripheral walls of the drug’s reservoir compartment are 
completely sealed to prevent any direct contact of the gastric mucosal 
surface with the odorless drug. The flotation chamber in the stomach, 
which contains diffused air, floats above the gastric contents for the 
improved efficiency of drug delivery system. The gastric fluid enters 
through the pores; the drug dissolves and carries the dissolved drug for 
continuous transport into the intestine for absorption.
Alginate beads
Several units of floating dose forms have been developed from freeze-
dried calcium alginate. Spherical beads with a diameter of about 2.5 
mm can be prepared by leaving sodium alginate solution in an aqueous 
solution of calcium chloride, which causes precipitation of calcium 
alginate. The beads are then separated and solidified in liquid nitrogen 
and freeze-dried – 24 h for 40°, which leads to the formation of a porous 
system that can maintain floating power above 12 h.
Hollow floating microsphere
Floating microspheres are GRDDS based on the non-effervescent 
approach. Hollow microspheres (micro-balloons) are, in a strict 
sense, spherical empty particles without a core. These microspheres 
Fig. 5: Gastroretentive drug delivery system based on 
mucoadhesion
Fig. 7: Gastroretentive drug delivery system based on high density
Fig. 6: Gastroretentive drug delivery system based on the 
combination of polymer swelling and effervescence
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are typically free-flowing powders contains proteins or synthetic 
polymers, ideally <200 μm in size. Solid biodegradable microspheres 
involving a drug dispersed or dissolved during the particle-matrix 
can control drugs. Gastroretentive floating microcephases are low-
density systems with sufficient buoyancy to float on gastric contents 
and remain in the stomach for a long time. As the system floats on the 
gastric contents, the drug is slowly released at the desired rate resulting 
in an increase in gastric retention with less fluctuation in plasma drug 
concentration [26].
Advantages of floating microspheres
•	 Enhanced bioavailability
•	 Enhanced first-pass biotransformation
•	 Sustained drug delivery/reduced frequency of dosing
•	 Targeted therapy for local ailments in the upper GIT
•	 Reduced fluctuations of drug concentration
•	 Improved receptor activation selectivity
•	 Reduced counter-activity of the body
•	 Extended time over critical (effective) concentration
•	 Minimized adverse activity at the colon
•	 Site-specific drug delivery
•	 Less inter- and intra-subject variability
•	 Minimizes the counter activity of the body leading to higher drug 
efficiency
•	 Fluctuations in drug concentration are minimized. Therefore, 
concentration-dependent adverse effects can be reduced
•	 Sustained mode of drug release enables the extension of the time 
over a critical concentration and thus enhances the pharmacological 
effects and improves the clinical outcomes
•	 Flexibility in DF design
•	 Extend patent protection, globalize products, and provide new 
business opportunities [19-22].
Disadvantages of floating microspheres
•	 These systems require a high level of fluid in the stomach for drug 
delivery so that they can float and work efficiently
•	 Not suitable for drugs that have solubility or stability problems in 
GIT
•	 If drugs such as nifedipine that is well absorbed with the entire GIT 
and which undergoes metabolism first, may not be desirable
•	 Drugs that are irritating to gastric mucosa also not suitable
•	 Acid intoxicants that are unstable in the acidic environment of the 
stomach are not suitable candidates for inclusion in the system
•	 The DF should be administered with a full glass of water (200–250 ml)
•	 These systems are no more beneficial than conventional DFs for 
drugs that are absorbed into the GIT [27,28].
METHOD OF PREPARATION OF FLOATING MICROSPHERE
The following methods are used for the preparation of a floating 
microparticulate drug delivery system.
•	 Emulsion solvent evaporation technique
•	 Emulsion cross-linking technique
•	 Emulsion-solvent diffusion technique
•	 Emulsification heat stabilizing technique
•	 Multiple emulsion methods










•	 Ionic gelation technique
•	 Hydroxyl appetite (HAP) microspheres in sphere morphology
•	 Hot melt microencapsulation technique.
EMULSION SOLVENT EVAPORATION TECHNIQUE
The coating polymer is dissolved in an organic solvent that is 
incompatible with the liquid production vehicle. The main material 
(a water-soluble or insoluble substance in water) dissolves or 
disperses in the coating phase with agitation. The above solution 
is spread over the phase of the liquid production vehicle to obtain 
the appropriately sized microcapsules. If the mixture is heated to 
evaporate the solvent, the polymer shrinks around the core and this 
process is described in Fig. 8, if the core material coating dissolves 
in the polymer solution, the matrix type microcapsules will be 
formed [25,26].
EMULSION CROSS-LINKING TECHNIQUE
This method is used for microparticles of natural carriers. The 
natural polymer dissolves in an aqueous medium and then a non-
aqueous medium is added. The drug is dissolved in an aqueous 
solution of a gelatin carrier that has previously been heated to 40°C 
for 1 h. The resulting solution is added dropwise in the oil phase, 
such as liquid paraffin, with a suitable surfactant at a stirring speed 
of 1500 rpm for 10 min at 3°C. Stir the resulting W/O emulsion again 
for 10 min at 15°C. The microspheres are washed with suitable 
organic solvents such as acetone and isopropyl alcohol and dried 
in air. The formed microspheres are dispersed in 5 ml of aqueous 
Fig. 8: (a and b) Emulsion solvent evaporation technique [29]
ba
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glutaraldehyde saturated toluene solution at room temperature for 
3 h and then cross-linked, further treated with 100 ml of 10 mm 
glycine solution containing 0.1% w/v of tween 80 at 37°C for 10 min 
to stop the cross-linking. The main disadvantage of this method is 
excessive exposure to active ingredients in chemicals when they are 
added at the time of preparation and then centrifuged, washed, and 
separated. Natural surfactants used to stabilize the emulsion phase 
can greatly affect the size, size distribution, surface morphology, 
loading, drug release, and biological performance of the final multi-
particulate product [30].
EMULSION-SOLVENT DIFFUSION TECHNIQUE
In this method Fig. 9, the drug is first dissolved in ethanol and 
dichloromethane (DCM) in a suitable polymer solution. This 
pharmaceutical polymer solution is added to a sodium lauryl sulfate 
solution, which is stirred for 1 h at 150 rpm at room temperature by 
a propeller-type agitator, washed, and dried in a desiccator at room 
temperature goes. Floating microspheres prepared by this method have 
improved residence time in Colone [31].
Emulsion heat stabilizing technique
The aqueous polymer solution is prepared by dissolving polymer 
such as egg albumin in water in the presence of surfactants such 
as Tween 80 by mechanical stirring for 30 min. Similarly, the oil 
phase is prepared by mixing 20 ml of suitable oil and 5 ml of diethyl 
ether with 1% span 80 (as an emulsifier) by magnetic stirring. 
The further oil phase is added to the aqueous phase by stirring at 
800–1000 rpm for 30 min. The above primary emulsion is added 
to preheated (65–70°C) oil by passing through the needle (No. 
21) and stirred at 1000–1200 rpm for 2 h till the solidification of 
microspheres takes place. The resulted microsphere suspension 
is cooled to room temperature by magnetic stirring. Then, 100 ml 
of anhydrous ether is added. The above suspension is centrifuged 
for 15 min, washed with ether to remove oily trace. The obtained 
microspheres are then dried in vacuum desiccators overnight and 
stored at 4°C in the dark [33].
Single emulsion technique
The microsphere of the natural polymer was prepared by the single 
emulsion technique. Natural polymers are dissolved in an aqueous 
medium followed by dispersion in a non-aqueous medium such 
as oil. In the next step, the cross-linking of the dispersed globules is 
performed using a chemical cross-linking agent or with the aid of heat. 
Glutaraldehyde and formaldehyde are used as chemical cross-linking 
agents.
Multiple emulsion method
This method Fig. 10 is suitable for water-soluble drugs such as 
proteins and peptides. The primary emulsion, o/w type, is prepared 
by dissolving an emulsifier containing a drug in an aqueous protein 
solution. The dispersed phase, which consists of the lipophilic 
organic phase, is added to it. The obtained primary emulsion is then 
subjected to homogenization by the addition of an aqueous solution of 
polyvinyl alcohol, resulting in a double emulsion. It is then subjected to 
evaporation solution [34].
Fig. 9: Emulsion-solvent diffusion technique [32]
Fig. 10: preparation of microspheres by multiple emulsion 
technique [35]
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Coacervation phase separation technique
This process mainly involves the following steps:
•	 Step-1: The core material is dispersed in a coating polymer solution
•	 Step-2: The coating is accomplished by controlled physical mixing 
of coating solution and core material in the liquid manufacturing 
vehicle phase
•	 Step-3: Hardening of coating polymer in the following ways-
Thermal change
The polymer is dissolved in cyclohexane by vigorous stirring at 80°C. 
The drug is added to the above solution with constant stimulation. 
The microsphere is obtained reducing the temperature by keeping in 
the ice bath. The product is washed twice with cyclohexane and air-
dried.
Non-solvent addition
Initially, the polymer is dissolved in toluene containing 
polyisobutylene in closure and shaken for 6 h at 500 rpm and the 
drug is discrete. The resulting solution is added to benzene with 
constant excitation. The microcapsules are washed with n-hexane 
and air-dried for 2 h.
Polymer addition
The microspheres are formed by dissolving polymer (ethylcellulose) 
in toluene, methylene blue is added as core material. Coacervation is 
accomplished by the addition of liquid polybutadiene. The polymer 
coating is strengthened by adding a non-solvent (hexane). The resulting 
product is washed and air-dried.
Salt addition
An oil-soluble vitamin is dissolved in corn oil and mixed in a gelatin 
solution at 50°C. Coacervation is done by adding sodium sulfate, 
resulting in a uniform coating of gelatin. Microspheres are collected and 
washed, cooled, and dried.
Polymer-polymer interaction
In this process, a homogeneous polymer solution is obtained by 
mixing an aqueous solution of an equal amount of gum arabica and 
gelatin (isoelectric point 8.9). The above solution is diluted twice 
with their volume of water, adjusted to pH 4.5, and heated to 40–45°C. 
Paradoxically charged macromolecules interact with these conditions 
and undergo coacervation. The liquid core material is added to 
the polymer solution and shaken well while maintaining the warm 
temperature. The mixture is then cooled to 25°C and the coating is 
hardened by cooling the mixture to 10°C [36,37].
An aqueous or organic solution of polymer
Drug is added
The drug is dissolved in the polymer solution
Phase separation is carried out 
Polymer rich globules
Hardening 
Microsphere in an aqueous or organic phase
Separation, washing, and drying          
Microsphere
Spray drying technique
The polymer is dissolved in a suitable volatile organic solvent such as 
DCM and acetone Fig. 11. The drug is added to the polymer solution 
under high-speed homogenization. The atomization of upward 
dispersion in a hot air stream leads to the formation of small droplets 
or fine mist. The solvent evaporates rapidly, forming microspheres of 
size range 1–100  μm. The microspheres are separated from the hot air 
Fig. 12: Suspension polymerization
Fig. 11: Spray drying technique [39]
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employing a cyclone separator. A major advantage of this procedure 
is the possibility of operation under aseptic conditions, leading to the 
formation of rapid and porous microparticles, which can be used for 
poorly soluble drugs [38,39].
Polymerization technique









Polymerization is initiated by heating a monomer or a mixture 
of monomers as well as initiators or catalysts, drug is loaded 
simultaneously. Although it is a simple technique, it cannot be applied 
to thermolabile active ingredients.
Monomer + Drug + Initiator 
Heating            Polymerization 
Polymer block    
Molding   Mechanical fragmentation  
Microsphere
Suspension polymerization/Pearl polymerization
In this pearl polymerization method Fig. 12, the monomer mixture is 
heated at lower temperatures than the polymerization, with an active 
drug as droplet dispersion in continuously in the aqueous phase. Particle 
size microspheres are usually <100 μm. Emulsion polymerization is 
carried out in the presence of an initiator in the aqueous phase at low 
temperature in suspension form. The outer phase usually consists of 
water through which heat can be easily dissipated. The formation of high 
polymer is possible by these techniques, but sometimes the polymer can 
be combined with non-reactive monomers and other additives.
Monomer + Drug + Initiator
Dispersion in the aqueous phase  
Heating and agitation    Polymerization 
Microspheres
Interfacial polymerization
It involves the reaction of various monomers at the interface between 
the two immersed liquid phases to form a film of the polymer that 
essentially covers the dispersed phase. Two reactive monomers are 
employed in this technique; one dissolved in the continuous phase 
while, others dispersed in the continuous phase (aqueous), during 
which another monomer is emulsified (Fig. 13) [39,40].
Ionic gelation technique
This technique has been used successfully by low-density polymers and gas-
producing agents such as tartaric acid and citric acid. The polymer solution 
of an aqueous solution is prepared by dissolving the polymer in water. The 
main material which is finely sieved (sieve No. 120) is added to the polymer 
solution and mixed to form a smooth viscous dispersion. This dispersion 
is added drop wise into through a 0.55 mm diameter fine needle syringe 
10% w/v CaCl2 solution. It is treated by stirring for 15 min at 200 rpm 
resulting in a spherical rigid microsphere. Finally, the microspheres are 
collected and dried in an oven at a temperature of 45°C for 12 h Fig. 14 [41].
HAP microspheres in sphere morphology
The HAP granules used in this process are obtained by the method 
of precipitation, followed by a spray drying process. The first 
microspheres are prepared by an emulsion of oil-in-water, followed 
by solvent evaporation technique. The oil-in-water emulsion obtained 
by dispersing in the organic phase (DCM solution containing 5% of 
Ethylene-vinyl acetate) and the appropriate amount of HAP in an 
aqueous medium of surfactant. When dispersed in the aqueous phase, 
the organic phase is turning into small droplets and each droplet is 
surrounded by surfactant molecules. Thus, a protective layer is formed 
Fig.14: Ionic-gelation technique [41]
Fig. 13: Interfacial polymerization [40]
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on the surface that prevents the droplets from coalescing and helps 
individual droplets to remain. While stirring, DCM slowly evaporates 
from the droplets and after the complete removal of DCM, the droplets 
harden to become individual microspheres. The size of droplets formed 
depends on many factors such as types and concentration of stabilizing 
agents and type and speed of stirring employed, which in turn affects 
the size of the final microspheres formed [42].
Hot melt microencapsulation technique
In this method, the polymer is melted and then mixed with the solid 
particles of the drug which has been sieved to <50 μm. The mixture 
is suspended by continuous stirring in a non-soluble solvent such as 
silicone oil and heated to 5°C above the polymer’s melting point. Once 
the emulsion has stabilized, it cools until the solid particles freeze. The 
resulting microspheres are washed by decay with petroleum ether. 
This method is suitable for the water labile polymers, for example, 
poly anhydrides. Microspheres with a diameter of 1–1000 μm can be 
obtained. Particle size can be distorted by changing the stirring speed. 
The only disadvantage of this method is the moderate temperature at 
which the drug is exposed [43].
CHARACTERIZATION OF GASTRORETENTIVE DFS
At present, clinical studies with humans are still the gold standard 
for investigating the function of new gastroretentive systems. 
Due to the high costs caused by in vivo studies as well as various 
disadvantages affecting the interpretation of in vivo data, powerful 
in vitro methods are needed for the initial evaluation of the behavior 
of new gastroretentive concepts. The following sections provide 
an overview of the most frequently used in vitro methods and will 
enable the reader to critically evaluate data obtained with these 
methods (Fig. 15-17).
In vitro and in vivo methods to characterize GRDF, the probe can be 
divided into the following groups based on the parameter:
•	 In vitro assessment of drug release behavior
•	 In vivo assessment of gastroretentive properties.
In vitro assessment of drug release behavior
One of the most widely studied parameters of GRDFs is their drug 
release behavior, preferably in biorelevant conditions. However, the 
Fig. 16: Schematic of the “custom-built stomach model” [53]
Fig. 15: Compendia dissolution apparatus and modifications [45]
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poorly anticipated backlog in vivo drug release is one of the most 
abandoned facts in this regard. Interestingly, the majority of scientists 
rely on compendial dissolution test apparatuses, which is generally 
applicable to the investigation of drug release from oral DFs. However, 
it is commonly accepted that gastric conditions have a sharp effect 
on drug release behavior, even for normal oral DFs. Considering the 
physiological condition in the human stomach, mandatory methods are 
best applied for quality control purposes but are generally not suitable 
for studying the drug release of GRDFs [39,40]. Nevertheless, devices 
such as the rotating basket or the paddle apparatus, as well as simple 
modifications of these tools are widely applied to GRDFs testing [44,47]. 
It is clear that the outcome of such tests largely depends on the type 
Apparatus shown in Fig. 15-19 of GRDF examined. In particular, for 
low-density and, thus, floating GRDF, dissolution testing in computer 
evaluation can be problematic, as the relatively large surface area of the 
system is not exposed to the dissolution medium [46]. Several methods 
have been suggested to interrupt the flotation of oral DFs during 
dissolution testing. Helical wire sinks are the easiest and most widely 
accepted process to use [48]. However, when examining floating and at 
the same time checking the expansion system, the use of a sinker may 
interfere with the swelling behavior of the DF  [45]. An alternative is to 
have a floating system under the ring mesh.
Pillay et al. and Durig et al. proposed a setup in which they introduced 
one and two stainless steel ring meshes, respectively, in the paddle 
apparatus [46,49]. The purpose of this study was to produce more 
reproducible data. However, these methods are far from physical 
conditions.
Another very simple approach was recently demonstrated by Kong 
et al. [50] who used a shaker incubator at a temperature of 37°C 
at 100 rpm. At the specified time point, samples were taken and the 
medium was changed.
Eberle et al. suggested a similar approach and referred to it as a 
“custom-built stomach model.” With this device, they tried to stick 
the DF to the paddle shaft and avoid constant contact with air. It 
consists of Erlenmeyer flasks, filled with 400 ml of medium and fixed 
in a water-bath shaker [51]. Overall, this setup released the apparent 
acceleration drug of a test floating system compared to a simple USP 
II paddle equipment setup. However, it has to be kept in mind that, in 
the paddle system, the DF was able to freely hover over the medium 
surface. In this region, the shear stress is low, which gives a good 
insight into the obtained results [52,53]. The artificial nature of this 
setup may allow for more fertile measurements but, presumably, it 
will not be reflected in in-vivo behavior due to lack of physiological 
relevance.
Parikh et al. [54] identified the pH difference of the GIT as a major issue 
that should occur in the dissolution test of GRDF in combination with 
particularly weak basic drugs. Based on the Rosette-Rice apparatus, 
they created a multi-compartment transfer model consisting of a gastric, 
a bowel, and an absorption compartment. In this device, the drug is 
freely transferred from the gastric to the intestinal compartment, while 
the absorption and intestinal compartment are separated by a filter 
membrane. The pH of the media can be adjusted through reservoirs 
containing 1 N HCl or borate buffer. Demonstrated potential benefits of 
an in-vitro system for a controlled release floating system compared to 
immediate-release tablets [47,54]. However, the in vitro dissolution and 
absorption profile may have also observed for a similar, non-floating 
controlled release system.
In contrast to the floating dose form, drug release testing of 
mucoadhesive systems using complex dissolution test methods seems 
less complicated. Therefore, in many cases, a paddle tool and a rotating 
basket tool are used for this purpose. However, since mucoadhesive 
systems are designed to adhere to the gastric mucosa, it would be 
misleading to study drug release if the dissolution medium is in full 
contact with the entire surface. Consequently, drug release can be 
extremely surprising. In a study by Llabot et al., cyanoacrylate glue was 
used to fix one side of the monolithic system in the metal discs tested 
during disruptive experiments [55].
A step toward further physiological dissolution test of novel GRDFs 
was made by Nakagawa et al. [56], using a modified version of the 
USP II paddle apparatus proposed by Aoki et al. In this model, the 
dissolution vessels of the paddle apparatus are filled with a polystyrol 
beads to mimic physiological stress in the stomach [57,58]. Nakagawa 
et al. applied this device to a novel GRDF and showed that one of the 
tested aggregates did not release the drug due to a lack of mechanical 
strength [62].
Fig. 17: Schematic of the multicompartment dissolution 
apparatus [50]
Fig. 19: Schematic of the dissolution stress test device [56]
Fig. 18: Schematic of the paddle-bead method [54]
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Similar observations were recently made using a so-called dissolution 
stress test device [59]. This device was developed by Garbacz et al. [56] 
and uses an inflatable balloon to bring real pressures on DFs. By applying 
postprandial SmartPill data, we were able to simulate extensive gastric 
pressure profiles as they occur in vivo. After examining the drug 
release behavior of marketed gastroprotective DFs, it can be seen 
that no system was able to withstand these stresses [60]. These data 
suggested that significant pressure sensitivity is one of the major issues 
to consider during the development of novel GRDFs. In addition to drug 
release behavior, gastroretentive properties are also endangered by 
intragastric stresses, even in postnatal conditions.
The mechanism of drug release from swellable matrices is determined 
by several physico-chemical phenomena. Among them, polymer water 
uptake, gel layer formation and polymeric chain relaxation are currently 
regarded as primarily involved in the modulation of drug release [61]. 
In addition to dissolution stress testing tools, there have been recent 
developments toward more physically relevant coherent testing of DFs. 
In vitro models to simulate gastric physiology include TNO’s TIM-1 
system, human gastric simulator, and dynamic gastric model [51,52]. 
However, none of them have yet been used for drug release testing 
of GRDFs, but most of them have the potential to characterize such 
systems in a relevant manner.
Drug-excipients interaction studies
Assessment of possible incompatibilities between an active drug 
substance and different excipients forms an important part of 
the preformulation stage during the development of solid dosage 
forms [61]. Fourier Transform Inferred (FTIR) spectroscopy was 
carried out to check the compatibility between drug and polymer. The 
excipients used were HPMC K4M, HPMC K15M, and Ethyl cellulose [63].
Stirring rate
To observe the effect of movement speed on the size of the resulting 
microspheres, formulations on different movement speeds; 300 rpm, 
500 rpm, and 100 rpm. The size of the resulting microspheres decreased 
within creasing agitation, but the increase was not statistically 
significant. It can be speculated that the movement speed was not able 
to break the effects of the stirring rate on microsphere prepolymer into 
finer droplets during the study [64].
Temperature of preparation
Sato et al. have studied the optimum preparation temperature 
concerning the microsphere cavity formation. The solution drug and 
polymer were poured into an aqueous solution of polyvinyl alcohol at 
various temperatures, that is, 20, 30, 40, and 50°C. They concluded that 
preparation at 20 or 30°C provided perforated microspheres, which 
are high pores along the surface that crumble when touched. Although 
the corresponding apparent particle densities of the resulting hollow 
microspheres were low, both buoyancies were low, probably due to easy 
penetration of the dissolution medium through the porous surface [65].
Plasticizers
Plasticizer concentration affects the rate of release of drug from 
the surface of microspheres. They have found that the addition of 
plasticizer makes the material wall more elastic and flexible so that it 
never brittle or broken under pressure. It was also observed that drug 
release increased significantly with the increasing concentration of 
plasticizer [66].
The volume of the aqueous phase
Use of various volumes affects formation of hollow microspheres. He 
observed that the potential advantage of using large volumes of the 
external aqueous phase was the lack of necessary stirring time. The 
solubility of DCM in water is 1% w/v. Diffusion of DCM, using a large 
volume (400–500 ml) compared to the volume of 200 ml, the aqueous 
phase, and hence the freezing of particles, occurred faster [67].
In vivo assessment of gastroretentive properties
To provide evidence of in vivo efficacy of GRDDS, an in vivo study is 
requires a well-designed animal model or humans. In vivo studies provide 
information about the GRT and bioavailability of the drug. The first 
requirement is to select an animal model for a successful in vivo study. For 
example, in small animals such as mice, rats, guinea pigs, and rabbits, there 
may be an issue dealing with animals, especially for large DFs [68,69]. As a 
result, measurements of the GRT and bioavailability are still difficult [70].
Therefore, most of the works of literature on the formulation of GRDDS 
showed evidence of in vivo gastric retention in relatively large size 
animals such as dog or human as well as in vitro characterization 
studies such as dissolution study, estimation of floating lag time, and 
floating duration [71]. In vivo gastric retention was hypothesized that 
GRDDS would provide superior therapeutic efficacy over conventional 
DF. Several sophisticated visualization techniques are helpful in this 
regard. Gamma scintigraphy is one such popular and elegant technique 
for proper evaluation of gastroretentivity in humans [72]. A small 
amount of radioisotope with a short half-life is included in the DF. 
The formulation has come into a neutron source, which allows it to 
release the captured gamma rays as an image after being processed by 
a computer [73,74].
Badve et al. [75] fabricated hollow calcium pectinate beads of diclofenac 
sodium for its chronopharmacological action. The floating beads were 
structurally hollow spheres with a bulk density of <1 g/ml and a 
porosity of 34%. An in vivo study on rabbits was performed by gamma 
scintigraphy showing gastroretention of beads up to 5 h. There have 
been several other recent reports of success in vivo gastric retention of 
floating tablets and microspheres containing versatile drug molecules 
such as ascaridole, calcium-disodium edentate, and repaglinide [76,77]. 
Magnetic resonance imaging is another technique to prove in vivo 
gastroretention of a GRDDS. This is a relatively safe technique that 
uses magnetic fields and radio waves to visualize the entire anatomical 
structure with the location of the entire DF [78]. Compounds with 
superparamagnetic properties (such as ferrous oxide) are included for 
visualization [79].
Steingoetter et al. [80] used this technique to report the in vivo gastric 
retention of Fe3O4 containing gadolinium chelates (Gd-DOTA) as a 
superparamagnetic agent and in analyzing intra-gastric tablet status 
and residence time in human volunteers were successful. Radiology 
or X-ray is another alternative technique where a radio-opaque 
material with the GRDDS is included. This technique has been noted 
in the evaluation of gastroretentivity, the rate of disintegration of DFs, 
and their esophageal transit [81]. To diagnose and monitor the GIT, 
gastroscopy is another commonly used technique. This technique uses 
fiber optics or a video system to detect DF. Since this procedure is less 
convenient, it is sometimes used to assess gastric retention in any DF 
in humans with minor anesthesia [82]. However, in the case of dogs, 
complete anesthesia is required, as reported by Dhiman et al. [79].
Animal study
Klausner et al. [83] developed a novel controlled release GRDDS of 
Levodopa using polymeric membranes with extended dimensions and 
high stiffness. In vivo studies were performed with the beagle dogs 
treated with carbidopa. The developed formulation was administered 
and the location of the DF in the GIT was determined by the X-ray. 
Furthermore, serial blood samples were taken for active medicine and 
tested. It has been revealed that the optimized controlled release of 
Levodopa GRDDS can maintain therapeutic concentrations of levodopa 
(>500 ng/ml) above 9 h. The average absorption time was much longer 
than non-GR controlled release-particles and oral solution.
Jain et al. [67] a floating microsphere of repaglinide (hypoglycemic 
agent) is formed, where calcium silicate was used as a porous carrier 
and Eudragit as polymer. Sprague–Dawley male rats were subjected to 
organ distribution studios and suspension of 99mTc-labeled floating 
microspheres was given orally with water to albino rabbits. After 6 h of 
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gastric residence times, confirmed by gamma scintigraphy, rats were 
sacrificed and organs separated (abdominal and intestinal region). The 
organ distribution of the test compound was found to be uniform and the 
associated bioavailability was 3.17 times higher than the marketed tablets.
In vivo, anti-tumor studies were conducted by Shishu and Aggarwal [84] 
to investigate the therapeutic efficacy of 5-fluorouracil of floating 
calcium alginate beads. It was found that the multiple-unit floating 
system was able to reduce the incidence of gastric tumors in mice 
by 74%, whereas as a conventional tablet dose, the reduction of this 
incidence was found to be only 25%.
Pande et al. [85] prepared cefpodoxime proxetil microspheres 
as GRDDS. The solvent evaporation technique was used for the 
development of the drug-loaded microspheres, where ethyl cellulose 
and HPMC were used as release retarded materials. Two groups of 
male albino rats were subjected to oral ingestion of the cefpodoxime 
proxetil microspheres and cefpodoxime proxetil suspension at a dose of 
10 mg/kg. Blood samples were collected from the retro-orbital region 
at pre-determined time intervals and centrifuged to separate plasma 
samples that were eventually analyzed by HPTLC. This study increased 
the relative bioavailability of the drug, prepared in microspheres, which 
is 1.5 times higher than in suspension.
Khan and Dehghan [86] reported increased bioavailability of 
atorvastatin calcium, which is given in albino rabbits in the form of 
floating tablets. With an in vitro floating lag time of 56±4.16 s and a 
floating duration of 6 h, tablets can increase bioavailability 1.6 times 
compared to conventional tablets.
The stomach is the main absorption site for cephalexin and 
gastroretentive formulation may achieve its increased bioavailability 
as confirmed by Yin et al. [87]. Cephalexin filled gastrofloating tablets 
were prepared by (HPMC K100M) as a matrix and sodium bicarbonate 
as a gas-forming agent. The developed tablets had a floating lag 
time of fewer than 15 s and a floating duration of more than 12 h, 
with an in vitro survival sustained-release profile for 12 h. In vivo, 
pharmacokinetic studies were conducted in fed and fasted beagle dogs 
compared with conventional capsules and sustained-release tablets. 
Cephalexin floating tablets resulted in relative bioavailability of 99.4% 
with an extended drug release profile, while reference formulations 
provided relative bioavailability of 39.3%. However, the study showed a 
significant effect on the pharmacokinetics of sustained-release tablets.
The combination of floating and bioadhesive was found to provide 
an improvement in the in vivo efficacy of famotidine minitablets 
manufactured by Zhu et al. [88] with HPMC K4M as release retarding 
and swollen polymer with Carbopol 971P (bioadhesive materials) and 
sodium bicarbonate (gas-forming agent). Tested in rat models, the 
mini-tablets could result in a 1.62-fold increase in bioavailability.
Qi et al. [89] in vivo success of the compression coated floating tablet of 
ofloxacin has been noted. The tablets were prepared by hydroxypropyl 
cellulose as a compression coating agent, sodium alginate, as a drug 
release modifier, and sodium bicarbonate as an effervescent agent. In vitro 
characteristics of the tablets such as a floating lag time of 30 s and floating 
duration of 12 h were well correlated with its relative bioavailability of 
172% compared to the market formulation studied in New Zealand rabbits.
The combination of effervescence and swelling floating mechanism as a 
means of improved gastroretentivity and in vivo efficacy was proved by 
Kadivar et al. [83] for imatinib mesylate sustained-release tablet prepared 
with HPMC K4M, sodium alginate, and Carbomer 934P. Studied in New 
Zealand rabbits, gastroretentive tablets can increase the bioavailability 
by about 1.5 times compared to the conventional tablets (Gleevec).
Human study
Chen et al. [90] developed a gastroretentive tablet based on swelling/
effervescence mechanism to administer the antihypertensive 
drug losartan with hydroxyethylcellulose, sodium carboxymethyl 
cellulose, and sodium bicarbonate. The tablets were found to float 
more than 16 h in vitro with swelling to 2 cm in diameter within 3 
h. In addition, the tablets showed a pH-dependent drug release with 
an extension of 24 h. When tested in healthy human volunteers, the 
optimized tablets achieved increased bioavailability relative to the 
immediate release market formulation of approximately 164% of the 
Kozar® name. As expected, gastroretentive floating tablets produced 
favorable pharmacokinetic parameters: Maximum residence time and 
Tmax values were higher and Cmax values were lower than those of 
commercial formulation.
Bomma and Veerabrahma [91] established the efficacy of antibiotic 
treatment over traditional tablets, Zocef®, with gastroretentive tablets 
of cefuroxime axetil. Developed and optimized tablets were based on a 
combination of swelling (HPMC and Polyox WSR 303) and effervescence 
(citric acid and calcium carbonate) mechanism. With an in vitro floating 
duration of more than 12 h with a floating lag time of fewer than 30 s, 
the optimized tablets can be retained 225±30 min in human subjects as 
confirmed by in vivo radiographic studies. Identical tablets were tested 
on eight healthy human volunteers. Developed floating tablets showed 
better bioavailability than Zocef tablets. A significant difference was 
observed in Cmax, Tmax, t1/2, AUC0–∞, based on in vivo performance, 
and mean residence time between test and reference (p<0.05). 
Compared to the reference tablets, the floating tablets of cefuroxime 
axetil increased relative bioavailability 1.61 times.
The in vivo efficacy of GRDDS as an active drug containing a high 
weight of nicotinamide (600 mg) was patented by Meijerink et al. [92]. 
Hypromellose was used as a swelling agent in that formulation. Eight 
healthy adult volunteers were used to ascertain their pharmacokinetic 
profiles. Blood samples as well as urine were collected at pre-
determined time intervals. The developed DF was able to maintain 
increased nicotinamide plasma levels in vivo for at least 8 h after 
ingestion by volunteers.
Ranade et al. studied ellagic acid and aloe vera gel powder as a bilayer 
floating tablet prepared with HPMC K15M and sodium bicarbonate to 
treat stomach ulcers. The researchers reported 75% ulcer blockage 
compared to 57% ulcer inhibition with ellagic acid alone. This efficacy 
was generated from tablets that appeared to have only a 4-h cumulative 
92% drug release in the in vitro floating period [93]
In another study, the efficacy of gastroretentive emulsion gel calcium 
pectinate beads approached cinnarizine prepared by the ionotropic 
gelation method was established by Abouelatta et al. [94]. Researchers 
reported that the average in vivo efficacy with a mean AUC0–24 and 
AUC0–∞ improved, respectively, increased by 1.79 and 3.80 times, that 
of conventional tablets in healthy human volunteers. Interestingly, the 
beads composed of pectin (base), glyceryl monooleate, and labrafac 
lipophile WL 1349 (oil phase) have in vitro floating capacity.
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